GILD - How To Earn $500 A Month From Gilead Sciences Stock | Benzinga
Shares of Gilead Sciences, Inc (NASDAQ: GILD) are trading higher during Friday’s trading session, bolstered by the Bank of America Securities bullish outlook on the stock.
Bank of America’s nod of confidence drew attention to the underappreciated growth avenues within Gilead Sciences' core HIV segment and its nascent ventures into hematology/oncology.
A Closer Look: Geoff Meacham, analyst at BofA Securities, took the stock from a Neutral rating to a Buy, lifting its price target from $88 to $95. Meacham pinpointed Gilead Sciences' HIV endeavors as an essential driver, set to grow in the coming years, especially with its "next-generation” asset, Lenacapavir.
Coupled with optimistic moves in hematology and oncology, powered by drugs like Trodelvy and Kite, the future looks bright for Gilead Sciences, according to Bank of America.
Related: Gilead Sciences Shares Trade Higher After Bullish ...